top of page

Coave Therapeutics and Théa Open Innovation sign exclusive agreement

Two agree to licensing, co-development, and commercialization agreement for Europe for CTx-PDE6b, a novel gene therapy candidate in retinitis pigmentosa

Press Release

Paris, France, 16th September 2021 – Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases, has entered into an exclusive licensing, co-development and commercialization agreement with Théa, a leading European speciality Pharma focused on ophthalmology. The agreement covers Coave’s lead investigational gene therapy candidate CTx-PDE6b (formerly HORA-PDE6b) for patients with PDE6b-associated Retinitis Pigmentosa (RP), an inherited retinal disease (IRD).

“We are delighted to sign this agreement with Théa for CTx-PDE6b, our most advanced candidate, which represents an innovative new gene therapy for people with Retinitis Pigmentosa,” said Rodolphe Clerval, CEO of Coave. “Théa is a leading European speciality pharma company in the field of Ophthalmology with world-class development expertise and commercial capabilities in major markets worldwide. We are very excited about the potential of CTx-PDE6b and look forward to building a successful relationship with Théa, as we advance this novel candidate through clinical development.”


Contact Information

Coave Therapeutics Rodolphe Clerval, CEO

MEDiSTRAVA Consulting Sylvie Berrebi, Eleanor Perkin, Mark Swallow PhD Tel: +44 (0)7714 306525

Laboratoires Théa Lorraine Kaltenbach, Director of Communication


bottom of page